|Awarded On||February 16, 2022|
|Title||Novel Chemical Probes Targeting Critical Protein-Protein Interactions in MLL-rearranged Leukemia|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Yongcheng Song|
Acute leukemia, including acute myeloid (AML) and lymphoid leukemia (ALL), is the most common (1 out of 3) cancer in children and adolescents. Particularly, leukemia caused by chromosome translocations involving mixed lineage leukemia (MLL) gene accounts for ~75% of leukemia in infants and ~10% in children/adults with a poor prognosis. Compared to other pediatric ALL with a 5-year survival of ~90%, that for MLL-rearranged ALL is only ~40%, and for very young infants, the survival is even less than 20%. MLL-rearranged AML patients have similarly poor clinical outcomes (5-year survivals of ~45%) to other AMLs.
Current treatments are chemo-drugs, which kill all rapidly proliferating cells inclu...